CONFLICT OF INTEREST DISCLOSURE
Mahendra Joshi and Shivkumar Madki are Directors of IDRS Labs Pvt. Ltd. with financial interest in the product. Dr. Archana Khosa Kakkar is an employee of IDRS Labs Pvt. Ltd. and has financial interest in the product. The remaining authors have no relevant conflicts of interest to declare.
REFERENCES
  1. Sharma H, Wadhwa R. Mercaptopurine. In: StatPearls . StatPearls Publishing; 2022. Accessed December 9, 2022.http://www.ncbi.nlm.nih.gov/books/NBK557620/
  2. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations | Leukemia. Accessed December 12, 2022.https://www.nature.com/articles/s41375-022-01591-4
  3. Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction. J Pediatr Hematol Oncol . 2014;36(7):503-517. doi:10.1097/MPH.0000000000000206
  4. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol . 2008;64(8):753-767. doi:10.1007/s00228-008-0478-6
  5. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med . 1983;308(17):1005-1009. doi:10.1056/NEJM198304283081705
  6. Bhatia S, Landier W, Hageman L, et al. High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children’s Oncology Group (COG) Study (AALL03N1).Blood . 2013;122(21):59. doi:10.1182/blood.V122.21.59.59
  7. Adam de Beaumais T, Fakhoury M, Medard Y, et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol . 2011;71(4):575-584. doi:10.1111/j.1365-2125.2010.03867.x
  8. Balis FM, Holcenberg JS, Poplack DG, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children’s cancer group and pediatric oncology branch study. Blood . 1998;92(10):3569-3577.
  9. Mulla H, Leary A, White P, Pandya HC. A Step Toward More Accurate Dosing for Mercaptopurine in Childhood Acute Lymphoblastic Leukemia.The Journal of Clinical Pharmacology . 2012;52(10):1610-1613. doi:10.1177/0091270011423663
  10. Vu K, Emberley P, Brown E, et al. Recommendations for the safe use and handling of oral anticancer drugs in community pharmacy: A pan-Canadian consensus guideline. Can Pharm J (Ott) . 2018;151(4):240-253. doi:10.1177/1715163518767942
  11. Breitkreutz J, Buckham J, Fischer R, Pöstges R, Boos J. Comparative in vitro studies on different 6-mercaptopurine formulations for use in children. Paediatric and Perinatal Drug Therapy. 2007;8:31-39. doi:10.1185/146300907X167817
  12. Hawwa AF, Collier PS, Millership JS, et al. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol . 2008;66(6):826-837. doi:10.1111/j.1365-2125.2008.03281.x
  13. Lennard L. Therapeutic drug monitoring of cytotoxic drugs.British Journal of Clinical Pharmacology . 2001;52(S1):75-87. doi:10.1111/j.1365-2125.2001.00366.x
  14. Chrzanowska M, Kolecki P, Duczmal-Cichocka B, Fiet J. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci . 1999;8(4):329-334. doi:10.1016/s0928-0987(99)00027-5
  15. Rosdiana DS, Setiabudy R, Andalusia R, et al. TPMT Genetic Variability and Its Association with Hematotoxicity in Indonesian Children with Acute Lymphoblastic Leukemia in Maintenance Therapy.Pharmgenomics Pers Med . 2021;14:199-210. doi:10.2147/PGPM.S288988
  16. Bhatia S, Landier W, Hageman L, et al. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. JAMA Oncol . 2015;1(3):287-295. doi:10.1001/jamaoncol.2015.0245
  17. Zhou Y, Wang L, Zhai XY, et al. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia. Br J Clin Pharmacol . 2020;86(8):1519-1527. doi:10.1111/bcp.14258
  18. Maintenance therapy of childhood acute lymphoblastic leukemia revisited—Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? - Schmiegelow - 2016 - Pediatric Blood & Cancer - Wiley Online Library. Accessed December 15, 2022.https://onlinelibrary.wiley.com/doi/10.1002/pbc.26139
  19. The Seventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Palermo, Italy, January 29–30, 2005 | Leukemia. Accessed December 15, 2022.https://www.nature.com/articles/2403783
  20. Tolbert JA, Bai S, Abdel-Rahman SM, et al. Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia. Pediatr Blood Cancer . 2017;64(8). doi:10.1002/pbc.26465
  21. Larsen RH, Hjalgrim LL, Grell K, et al. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol . 2020;86(1):25-32. doi:10.1007/s00280-020-04097-x
  22. Mulla H, Leary A, White P, Pandya HC. A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia. J Clin Pharmacol. 2012;52(10):1610-1613. doi:10.1177/0091270011423663
  23. Zhang F, Jia R, Gao H, Wu X, Liu B, Wang H. In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population. Clin Pharmacokinet . 2021;60(11):1373-1385. doi:10.1007/s40262-021-01045-7
  24. Liu T, Ghafoori P, Gobburu JVS. Allometry Is a Reasonable Choice in Pediatric Drug Development. J Clin Pharmacol . 2017;57(4):469-475. doi:10.1002/jcph.831
  25. Mulla H, Buck H, Price L, Parry A, Bell G, Skinner R. “Acceptability” of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia. J Oncol Pharm Pract . 2016;22(3):387-395. doi:10.1177/1078155215577808Tables